The vital Rafah border crossing between Gaza and Egypt has resumed operations for restricted humanitarian and civilian traffic, marking a critical, though tentative, development in the ongoing ceasefire agreement.
GitLab's strategic pivot to become an AI-centric development platform is facing heightened scrutiny from Wall Street. Recent analyst downgrades, citing competitive pressures and execution risks, have cast a shadow over the company's transformation efforts, even as its stock struggles to recover from significant declines over the past year.
Kuya Silver reports a record quarterly production haul from its Bethania silver mine alongside accelerated underground development, drawing investor focus. However, a premium valuation against a backdrop of ongoing losses presents a complex picture for the junior miner.
Travere Therapeutics faces a securities fraud investigation by Robbins Geller Rudman & Dowd LLP, raising questions about the accuracy of its past disclosures. The probe casts a shadow over the company's critical transition, as it banks on its kidney drug FILSPARI to drive growth amid mounting legal and commercial pressures.
As regional markets adjust to easing geopolitical pressures, a closer look reveals resilient performers. We analyze three small-cap stocks—R.A.K. Ceramics, TALCO Industrial, and Emilia Development—that are navigating the current volatility with strong fundamentals and potential for growth.
Minerals 260 (ASX:MI6) has significantly upgraded the resource estimate at its Bullabulling gold project to 4.5 million ounces, bolstered by strong drilling results and a solid cash position. The expansion shifts focus to the upcoming pre-feasibility study and execution risks as the company targets key development decisions by 2026.
Allegion (NYSE: ALLE) is accelerating its strategic shift toward integrated smart security platforms, emphasizing digital credentials, connected locks, and cloud-based access control to meet growing demand from commercial and institutional clients.
As BrightView Holdings prepares to report its fourth-quarter results, investors are watching closely to see if the commercial landscaping leader can halt a streak of revenue misses and navigate a challenging economic environment.
Exelixis has filed its next-generation therapy zanzalintinib with U.S. regulators for metastatic colorectal cancer, marking a significant step in its clinical development and potentially enhancing its competitive position in the targeted oncology space.
Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.
Archer Aviation secures a pivotal agreement with Serbia to supply its electric air taxis for EXPO 2027, marking a significant step into the European market and sparking discussions on its path to commercialization and valuation.
Mondelez International merges financial and operational oversight under veteran CFO Luca Zaramella, who assumes the additional role of Chief Operating Officer. The strategic move aims to tighten cost discipline across global commercial units but raises questions about succession planning and cash flow pressures as the snack giant navigates a challenging market.
After two punishing years, GitLab's shares have been battered by fears over AI's impact on coding. But with a strategic pivot to an AI-powered development platform and a resilient business model, 2026 could be the year the company turns the narrative around.
Intuit expands its ecosystem with a dual-pronged strategy, launching a career development program for accounting students while integrating Checkr's background check services directly into its payroll and enterprise platforms, aiming to solidify its role from talent cultivation to HR operations.
Merck & Co. shifts its cancer drug development playbook, opting for targeted collaborations with Guardant Health and Eikon Therapeutics after walking away from a major acquisition. Analysts debate whether the stock's current price fully reflects its long-term pipeline potential.
Deutsche Bank reported meeting its key 2025 financial objectives, including a 10.3% return on tangible equity, and outlined a path to boost profitability above 13% by 2028. The update, delivered during a fixed income call, highlighted revenue growth, cost discipline, and a strengthened balance sheet, even as management signaled caution on parts of the commercial real estate market.
Realtor.com ranks the Florida Keys among the nation's top luxury markets, where strict development limits and finite land create a high-stakes arena for elite buyers seeking a unique legacy, not just a second home.
Cullen/Frost Bankers (NYSE: CFR) reported fourth-quarter revenue in line with expectations but delivered a significant earnings beat, driven by its aggressive branch network expansion in Texas and robust commercial lending. Management expressed confidence in sustained loan growth and improving margins for the coming year.
Valley National Bancorp (VLY) reported fourth-quarter revenue and profit that topped Wall Street forecasts, driven by robust core deposit growth and disciplined balance sheet management. The regional bank's leadership pointed to strategic tech investments and commercial loan demand as key pillars for its 2025 outlook.
Analyst Tara Bancroft of TD Cowen lowered the firm's price target on Geron Corporation (GERN) from $4 to $3, maintaining a Buy rating ahead of the biotech's fourth-quarter results. The move reflects a model update as the company navigates mixed commercial progress for its blood cancer drug RYTELO.
